Prediction of response to drug therapy in psychiatric disorders.
Prediction of response to drug therapy in psychiatric disorders.
复制标题
DOI：
10.1098/rsob.180031
复制
发表时间：
2018-05
期刊：
影响因子：
5.8
通讯作者：
Gage FH
中科院分区：
文献类型：
--
作者：
Stern S;Linker S;Vadodaria KC;Marchetto MC;Gage FH
个性化医疗与许多医学领域的关系越来越密切，有望实现更有效的药物治疗和更早的干预。个性化医疗的发展与生物标志物和分类算法的识别相结合，有助于预测不同患者对不同药物的反应。在过去的10年里，美国食品和药物管理局（FDA）在肿瘤学、肺科、胃肠病学、血液学、神经病学、风湿病学甚至精神病学领域批准了多种标记为药物基因组学的基因预筛选药物。临床医生长期以来一直警告说，患者报告的看似相似的症状实际上可能是由不同的生物学原因引起的。随着越来越多的人被诊断出患有不同的精神疾病，科学家和临床医生开发针对个人情况的精准药物至关重要。全基因组关联研究强调了精神分裂症、双相情感障碍、重度抑郁症和自闭症谱系障碍等精神疾病的复杂性。在这些研究之后，需要进行关联研究来寻找特定疾病人群中个体患者对可用药物的反应性的基因组标记。除了 GWAS 之外，脑成像、细胞重编程、测序和基因编辑等新技术的出现使我们有机会寻找更多表征药物治疗反应的生物标志物，并使用所有这些生物标志物来确定治疗方案。在这篇综述中，我们讨论了为寻找四种脑部疾病（双相情感障碍、精神分裂症、重度抑郁症和自闭症谱系障碍）的不同可用药物的反应性生物标志物而进行的研究。我们提供使用集成方法的建议，该方法将利用现有技术更好地预测最合适的药物。
Personalized medicine has become increasingly relevant to many medical fields, promising more efficient drug therapies and earlier intervention. The development of personalized medicine is coupled with the identification of biomarkers and classification algorithms that help predict the responses of different patients to different drugs. In the last 10 years, the Food and Drug Administration (FDA) has approved several genetically pre-screened drugs labelled as pharmacogenomics in the fields of oncology, pulmonary medicine, gastroenterology, haematology, neurology, rheumatology and even psychiatry. Clinicians have long cautioned that what may appear to be similar patient-reported symptoms may actually arise from different biological causes. With growing populations being diagnosed with different psychiatric conditions, it is critical for scientists and clinicians to develop precision medication tailored to individual conditions. Genome-wide association studies have highlighted the complicated nature of psychiatric disorders such as schizophrenia, bipolar disorder, major depression and autism spectrum disorder. Following these studies, association studies are needed to look for genomic markers of responsiveness to available drugs of individual patients within the population of a specific disorder. In addition to GWAS, the advent of new technologies such as brain imaging, cell reprogramming, sequencing and gene editing has given us the opportunity to look for more biomarkers that characterize a therapeutic response to a drug and to use all these biomarkers for determining treatment options. In this review, we discuss studies that were performed to find biomarkers of responsiveness to different available drugs for four brain disorders: bipolar disorder, schizophrenia, major depression and autism spectrum disorder. We provide recommendations for using an integrated method that will use available techniques for a better prediction of the most suitable drug.
登录
查看更多内容
影响因子：
12.3
作者：
Carroll LS;Owen MJ
通讯作者：
Owen MJ
影响因子：
64.3
作者：
Chekroud, Adam Mourad;Zotti, Ryan Joseph;Corlett, Philip Robert
通讯作者：
Corlett, Philip Robert
DOI：
10.1007/s00406-014-0506-8
发表时间：
2015-02-01
影响因子：
4.7
作者：
Bares, Martin;Novak, Tomas;Hoeschl, Cyril
通讯作者：
Hoeschl, Cyril
影响因子：
168.9
作者：
Arranz, MJ;Munro, J;Kerwin, RW
通讯作者：
Kerwin, RW
影响因子：
11
作者：
Badner, JA;Gershon, ES
通讯作者：
Gershon, ES